Our study demonstrated that high FGFR1 amplification is not a common genetic alteration (8.7%) but presented as a delayed adverse prognostic factor in resected stage I-II ESCC patients. This evidence concerns the gene FGFR1 and esophageal squamous cell carcinoma.